Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| pc3 prostate |
|
Physical and functional interaction of androgen receptor with was seen between LNCaP and PC-3. Fig. 1. Differential sensitivity of the proliferation of LNCaP and PC-3 prostate. cancer cells to anti-calmodulin W-7. Melatonin receptors in PC3 human prostate tumor cells The human PC3 prostate cell line was obtained .. Effects of melatonin on CAMP and cGMP contents of human prostate PC3 cells. Cells grown at iow Silibinin suppresses in vivo human prostate PC-3 tumor xenograft Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor .. antitumor efficacy of silibinin against in vivo PC-3 prostate tumor Lysophosphatidic acid stimulates PC-3 prostate cancer cell prostate cancer cell invasion. PC-3 high invasive cells demonstrated constitutively .. PC-3 prostate cancer cells. LPA stimulated NF-kB DNA binding Human Cytomegalovirus Infection Alters PC3 Prostate Carcinoma Cell Immunoperoxidase staining of HCMV (HCMVHi)-infected PC3 prostate tumor cells. PC3 cells were infected at an MOI of 1 and were stained against the Science Links Japan | Cycloheximide Inhibits Resistance to Title;Cycloheximide Inhibits Resistance to Anticancer Agents in PC3 Prostate Cancer Cells After Heat Treatment. Author;AOKI KEIICHIRO(Showa Univ., PRCA1 - prostate cancer 1 For this, we generated human prostate cancer cells ( PC3) stably transfected . Decursin suppresses human androgen-independent PC3 prostate cancer cell Inhibition of PC-3 prostate cancer cell growth in vitro using both µM/L) known to have significant activity against the PC-3 prostate cell line in combination therapy with the. chemotherapeutic agent paclitaxel (Taxol) (2.5 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 The PC3 prostate cancer cell line expresses urokinase plasminogen activator which . The PC3 human prostate cancer cell line was originally purchased from Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Advances in Brief. Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human. Androgen-independent PC-3 Prostate Cancer Cells Both. in Vitro and in Vivo Decursin Suppresses Human Androgen-Independent PC3 Prostate Cancer -catenin and thus inhibited the growth of PC3 prostate cancer cells. In contrast, decursinol, in which the (CH3)2â“C=CHâ“COOâ“side chain of decursin is Decursin suppresses human androgen-independent PC3 prostate cancer Decursin suppresses human androgen-independent PC3 prostate cancer cell proliferation by promoting the degradation of {beta}-catenin. Gene Expression Profiles of Genistein-Treated PC3 Prostate Cancer Our previous studies have shown that genistein inhibits the growth of PC3 prostate cancer cells and induces apoptosis by inhibiting nuclear factor {kappa} Gene Expression Profiles of Genistein-Treated PC3 Prostate Cancer To better understand the precise molecular mechanism(s) by which genistein exerts its effects on PC3 prostate cancer cells, we utilized a cDNA microarray to Matrix Biology : Type I collagen-mediated proliferation of PC3 Type I collagen-mediated proliferation of PC3 prostate carcinoma cell line: implications for enhanced growth in the bone microenvironment European Urology : The Survival Effect of Prolactin on PC3 To our knowledge this study demonstrates for the first time a survival effect for PRL in PC3 prostate cancer cell line, possibly mediated by an IngentaConnect The Survival Effect of Prolactin on PC3 Prostate The Survival Effect of Prolactin on PC3 Prostate Cancer Cells. Authors: Ruffion A.1; Al-Sakkaf K.A.; Brown B.L.; Eaton C.L.; Hamdy F.C.; Dobson P.R.M. IngentaConnect Human Cytomegalovirus Infection Alters PC3 Prostate download Human Cytomegalovirus Infection Alters PC3 Prostate Carcinoma Cell Adhesion to Endothelial Cells and Extracellular Matrix 940.7607421875kb The survival effect of prolactin on PC3 prostate cancer cells. The survival effect of prolactin on PC3 prostate cancer cells. growth and survival of prostate cancer cells and the intracellular signalling mechanisms |
| pc3 prostate |
|
prostate bladder neck massaging pleasure prostate prostate and perineum massager milking the prostate how to |